Indegene Q3 Revenue Soars 30%, But PAT Dips Amid Acquisition Costs

TECH
Whalesbook Logo
AuthorVihaan Mehta|Published at:
Indegene Q3 Revenue Soars 30%, But PAT Dips Amid Acquisition Costs
Overview

Indegene reported a strong Q3 FY26 with revenue up 30.8% YoY to INR 9,421 million, boosted by acquisitions and organic growth. While PAT declined 6.5% YoY due to one-time acquisition costs and amortization, the company secured seven large deals exceeding $1 million ACV. Integration of BioPharm is on track, and a strategic focus on AI platforms positions Indegene for future growth, with management forecasting margin recovery to 20%.

📉 The Financial Deep Dive

Indegene Limited has posted a robust Q3 FY26 performance, with total revenue climbing 30.8% year-on-year (YoY) to INR 9,421 million. This significant top-line growth was a combination of acquisition synergies and a healthy 18.3% YoY organic revenue increase, excluding the BioPharm acquisition impact. In US Dollar terms, revenue grew 24.4% YoY.

Adjusted EBITDA saw a healthy increase of 15.7% YoY to INR 1,747 million, with margins expanding by 30 basis points quarter-on-quarter (QoQ) to 18.5%. However, Profit After Tax (PAT) registered a 6.5% year-on-year decline to INR 1,026 million. This was primarily attributed to INR 105 million in one-time, non-operational expenses related to three acquisition transactions and restructuring, alongside higher non-cash charges from amortization of intangibles from recent acquisitions. Despite the PAT dip, the company highlighted strong underlying cash flow generation, with Operating Cash Flow (OCF) to PAT at a robust 154%.

🚀 Strategic Analysis & Impact

The company announced significant deal wins in the quarter, including seven large deals each exceeding $1 million in Annual Contract Value (ACV). Notable wins include a multi-million dollar omnichannel orchestration deal and a $20 million Total Contract Value (TCV) end-to-end commercialization partnership. The integration of the BioPharm acquisition is proceeding as planned, with IT, HR, and finance transitions on track for completion by March 31, 2026. The strategic focus on AI platforms like Content Super App and NEXT Medical Writing Platform is intended to position Indegene as a leader in Gen AI-driven solutions for the life sciences sector.

🚩 Risks & Outlook

The primary risks for Indegene revolve around the successful integration of its acquired entities and the timely execution of large, complex deals. However, management expressed confidence in the resilient outlook for the life science industry, projecting a 5%-8% CAGR through 2029, driven by innovation and digital transformation needs. The company anticipates EBITDA margins to return to approximately 20% over the next 6-8 quarters, with sequential EBITDA improvement expected from Q1 FY27, signaling a recovery path post-acquisition costs. Investors will be watching the realization of cost synergies and the impact of AI initiatives on future revenue and profitability.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.